PureCycle Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PureCycle Technologies, Inc. (PCT) on November 3, 2025, covering events occurring on October 28, 2025. The filing addresses significant changes to the Company's Board of Directors, including the appointment of a new independent director and the resignation of an existing director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to director compensation and prior equity holdings:
- Director Equity Grant: Dr. Siri Jirapongphan received an initial annual non-employee director award of restricted stock units with a grant date value of $62,500 (prorated for six months).
- Prior Equity Holding: Dr. Jirapongphan previously purchased 300 shares of Series B Convertible Perpetual Preferred Stock for an aggregate price of $300,000 on June 20, 2025.
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Appointment: Dr. Siri Jirapongphan was appointed as a director effective October 28, 2025. He is expected to serve on the Operational Excellence Committee and is deemed independent under Nasdaq listing standards.
- Resignation: Jeffrey R. Fieler resigned from the Board effective immediately on October 30, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Resignation Compensation: In connection with his resignation, Mr. Fieler's 2025 non-employee director grant was immediately vested, prorated for the six months of service during the current term.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Jirapongphan's qualifications, citing his deep understanding of Thailand markets and technical expertise in chemical engineering and petrochemicals. His background includes roles as an independent director and Audit Committee Chairman at Bangkok Bank PLC, and previous leadership at IRPC PLC and PTT Global Chemical PLC. No specific risks, contingencies, or unusual items were disclosed in this filing beyond standard governance changes.
Investor Verification Checklist
- Verify the impact of the Board composition change on the Company's strategic direction, particularly regarding international markets in Thailand.
- Review the Company's Definitive Proxy Statement for the 2025 Annual Meeting (filed March 28, 2025) for details on the standard director compensation program.
- Confirm the status of Dr. Jirapongphan's 300 shares of Series B Convertible Perpetual Preferred Stock and any conversion rights.
- Monitor future filings for the appointment of a replacement for Mr. Fieler if the Board size is intended to remain constant.